Sino Biopharmaceutical ( (HK:1177) ) has issued an update.
Sino Biopharmaceutical Limited announced positive results from a phase III clinical study of Culmerciclib in combination with Fulvestrant for first-line treatment of HR-positive and HER2-negative advanced breast cancer. The study showed that the combination therapy significantly reduced the risk of disease progression or death, achieving statistical significance and clinical relevance. This development positions the company to address the significant unmet clinical needs in breast cancer treatment, particularly for the most common subtypes, and strengthens its market presence in the oncology field.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the biopharmaceutical industry. It develops innovative drugs, particularly targeting various subtypes of breast cancer, including HR-positive, HER2-positive, HER2-low expression, and triple-negative breast cancer, aiming to provide diverse treatment options for female patients.
YTD Price Performance: 17.26%
Average Trading Volume: 1,083
Technical Sentiment Signal: Sell
Current Market Cap: $8.67B
See more data about 1177 stock on TipRanks’ Stock Analysis page.